Viking Therapeutics
VKTX
11 hedge funds and large institutions have $72K invested in Viking Therapeutics in 2016 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 3 closing their positions.
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
57% more funds holding
Funds holding: 7 → 11 (+4)
54% less capital invested
Capital invested by funds: $158K → $72K (-$86K)
Top Buyers
| 1 |
Citadel Advisors
Miami,
Florida
|
+$26.2K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$5K |
| 3 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
+$3.63K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.81K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.96K |
Top Sellers
| 1 |
Goldman Sachs
New York
|
-$44K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$18K |
| 3 |
Creative Planning
Overland Park,
Kansas
|
-$10K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $29K | +$2.81K | +1,400 | +7% |
|
|
2
Citadel Advisors
Miami,
Florida
| $19K | +$26.2K | +13,044 | New |
|
3
Wells Fargo
San Francisco,
California
| $9K | – | – | – |
|
|
IA
4
IFP Advisors
Tampa,
Florida
| $6K | +$1.21K | +600 | New |
|
|
5
UBS Group
Zurich,
Switzerland
| $4K | +$5K | +2,485 | New |
|
|
6
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $3K | +$3.63K | +1,807 | New |
|
|
BFA
7
BlackRock Fund Advisors
San Francisco,
California
| $1K | +$1.17K | +582 | New |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| $1K | +$1.96K | +977 | New |
|
|
9
Goldman Sachs
New York
| – | -$44K | -12,826 | Closed |
|
|
10
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$18K | -3,125 | Closed |
|
|
11
Creative Planning
Overland Park,
Kansas
| – | -$10K | -3,000 | Closed |
|
12
Citigroup
New York
| – | +$201 | +100 | New |
|
VKTX Hedge Fund Activity: Q1 2016 in Review
11 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics (VKTX) for Q1 2016, worth a combined $72K — down 54% from $158K a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new VKTX positions and 3 closed out — a net gain of 4 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $26.2K. The largest seller was Goldman Sachs, exiting entirely with an estimated $44K sold.
- 11 institutional investors held Viking Therapeutics (VKTX) as of Q1 2016, up from 7 in Q4 2015.
- Funds reported $72K of Viking Therapeutics stock for Q1 2016, down 54% quarter-over-quarter.
- 7 funds opened new Viking Therapeutics positions in Q1 2016 and 3 closed out, a net change of +4 holders.
- The largest Viking Therapeutics buyer in Q1 2016 was Citadel Advisors, an estimated $26.2K added.
- The largest Viking Therapeutics seller in Q1 2016 was Goldman Sachs, an estimated $44K sold.
Based on aggregated 13F filings for Q1 2016.